脂质运载蛋白2联系肥胖和心血管疾病的临床证据和分子机制  

Clinical Evidence and Molecular Mechanism of Lipocalin-2 Linking Obesity and Cardiovascular Disease

作　　者：吴光雨[1,2] 李华婷[2] 贾伟平[2] 

机构地区：[1]苏州大学医学部,江苏苏州215000 [2]上海交通大学附属第六人民医院内分泌代谢科上海市糖尿病研究所上海市糖尿病重点实验室上海市糖尿病临床医学中心上海市代谢病临床医学中心,上海200233

出　　处：《医学综述》2014年第20期3649-3652,共4页Medical Recapitulate

基　　金：国家重大基础研究计划(973)(2011CB504001)

摘　　要：脂质运载蛋白2(lipocalin-2,LCN2)主要由脂肪细胞和多种上皮细胞分泌。过去的研究结果发现,LCN2参与肾脏损伤的病理生理过程,并可作为肾脏急慢性损伤的标志物。近期大量的临床证据表明,LCN2的水平与代谢性疾病及相关心血管疾病的发生与转归相关。LCN2通过调节炎性反应,参与糖脂代谢,促进内皮功能紊乱及粥样斑块形成,增加心肌损伤,促进心血管疾病的发生、发展。该文就LCN2联系肥胖及心血管疾病的临床证据及机制研究进行简要综述。Lipocalin-2 （LCN2） is predominantly produced in adipose tissue and epithelial cells.Previous studies have shown that it participates in the pathogenesis of kidney damage and is regarded as a biomarker.Recently,serum LCN2 level has been shown to be associated with the development of metabolic and cardiovascular diseases（CVD） in humans.Animal studies demonstrate that the increasing production of LCN2 contributes to the pathogenesis of CVD,probably by mediating inflammatory response,glucose and lipid metabolism,as well as promoting endothelial dysfunction,atherosclerosis,and cardiomyocyte apoptosis.Here is to make a review of the recent advances in the understanding of the role of LCN2 linking obesity and CVD from the perspectives of clinical evidence and mechanisms study.

关 键 词：脂质运载蛋白2 肥胖 心血管疾病 

分 类 号：R58[医药卫生—内分泌] R54[医药卫生—内科学]